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Introduction
Hypertension affects almost 29% of the adult US
population, an estimated 58.4 million individuals
(1). Worldwide, hypertension may affect as many as
1 billion individuals, with approximately 7.1 million
deaths per year attributable to the condition (2). The
prevalence of hypertension increases with advancing
age to the point where more than half of the people
aged 60–69 years of age and approximately three-
quarters of those aged 70 years or older are affected
(2). As a major risk factor for cardiovascular disease,
stroke, retinopathy, and renal failure, hypertension
has major global public health implications, and the
challenge of achieving effective blood pressure (BP)
control is growing in importance as populations age
throughout the world.
Maintaining aggressive BP targets is the basis of
preventing the long-term adverse outcomes of hyper-
tension. The linkage of efﬁcacious and prompt treat-
ment has been suggested by the results of the
VALUE trial, which was designed to compare the
incidence of cardiac morbidity and mortality when
the same level of BP control was achieved using
treatment regimens based on the angiotensin recep-
tor blocker (ARB) valsartan or the calcium channel
blocker amlodipine (3). However, BP was in fact
controlled more rapidly and to a slightly greater
degree in the amlodipine arm during the early
months of the trial, and this difference was correlated
with a signiﬁcantly higher incidence of myocardial
infarction and a trend towards a higher incidence of
stroke in the valsartan group where BP was less effec-
tively controlled (3). The time relationship of excess
events in the valsartan group compared with amlodi-
pine can best be explained by the between-group dif-
ferences in BP, which were largest in the ﬁrst year.
Overall, 63% of the entire observed excess of strokes
OnlineOpen:This article is available free online at www.blackwell-synergy.com             
SUMMARY
Background: Evidence-based guidelines for the management of hypertension are
now well established. Studies have shown that more than 60% of patients with
hypertension will require two or more drugs to achieve current treatment targets.
Discussion: Combination therapy is recommended as ﬁrst-line treatment by the
JNC-7 guidelines for patients with a blood pressure > 20 mmHg above the systolic
goal or 10 mmHg above the diastolic goal, while the International Society of
Hypertension in Blacks recommends combination therapy when BP exceeds targets
by > 15/10 mmHg. Current European Society of Hypertension-European Society of
Cardiology guidelines also recommend the use of low-dose combination therapy in
the ﬁrst-line setting. Furthermore, JNC-7 recommends that a thiazide-type diuretic
should be part of initial ﬁrst-line combination therapy. Thiazide/diuretic combina-
tions are available for a variety of classes of antihypertensive, including ACE inhibi-
tors, angiotensin receptor blockers (ARBs), beta blockers and centrally acting
agents. This article focuses on clinical data investigating the combination of an
ARB, irbesartan, with the diuretic, hydrochlorothiazide. Conclusions: These data
indicate that the ARB/HCTZ combination has greater potency and a similar side
effect proﬁle to ARB monotherapy and represents a highly effective approach for
attaining goal BP levels using a therapeutic strategy that very effectively lowers
BP, is well tolerated and minimises diuretic-induced metabolic effects.
Review Criteria
The PubMed and other searchable databases were
utilized to collate information from original and
review articles as well as from selected abstracts
relevant to this topic.
Message for the Clinic
Diuretic-based combination antihypertensive drug
therapy is a cornerstone of antihypertensive drug
therapy. Most hypertensive patients will require
more than one antihypertensive drug to lower
blood pressure (BP) below target levels. The
combination of diuretics with renin angiotensin
system antagonists is highly logical given the
signiﬁcant augmentation of BP response and the
minimization of drug-speciﬁc side effects (e.g.,
hypo- and hyperkalemia) when these two drug
classes are combined. The combined use of
angiotensin receptor blockers and diuretics is better
tolerated, but more costly, than generic angiotensin
converting enzyme inhibitors and diuretics, mostly
because of the absence of cough and much lower
incidence of angioedema.
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of the ﬁrst year (3,4). These data might be inter-
preted as showing that the speed of attaining BP tar-
gets is important; however, it is also likely that the
withdrawal of antihypertensive drug therapy from
stable but severely hypertensive patients, followed by
subsequent randomisation to monotherapies that dif-
ferentially controlled BP early on, contributed to the
higher event rate early in the VALUE trial in the val-
sartan compared with the amlodipine treatment
arms. Nevertheless, therapeutic inertia contributes to
slow control of BP to target levels and plausibly con-
tributes to a modest augmentation of risk for pres-
sure-related events even over the short-term.
While BP goal attainment is the most crucial objec-
tive of antihypertensive treatment, other consider-
ations are also of fundamental importance. One key
consideration is that BP control should be sustained
over 24 h. Long-acting antihypertensive agents pro-
vide 24-h BP control from a single daily dose, as well
as attenuating the early morning rise in BP (5). Long-
acting, once-daily antihypertensive drugs also provide
greater protection against a rise in BP after missed
medication doses in intermittently non-compliant
patients. Treatment regimens should be designed to
support long-term treatment adherence. In this
regard, issues of patient education and the physician-
patient relationship are critical (6). When regarding
drug selection it is important to prescribe the simplest
possible dosage (7). Several studies have found that
once-daily dosage regimens are associated with better
compliance than twice-daily regimens (8). Within the
context of combination therapy, ﬁxed-dose combina-
tions in which treatment is administered as a single
daily pill enable the simplicity of treatment to be sus-
tained with a lower overall pill burden to the patient.
Tolerability is also crucial to adherence (7). Although
hypertension is generally considered to be asymptom-
atic, strong evidence suggests this assumption is incor-
rect (9,10). The use of antihypertensive medications
that compromise quality of life can be especially trou-
bling for many patients with uncomplicated hyperten-
sion. This may result in discontinuation of therapy
(11). Indeed, in one study the number of adverse
events associated with antihypertensive therapy, and
not the achieved BP reduction, was found to directly
correlate with changes in quality of life (12). In sum-
mary, treatment should be effective, with rapid and
aggressive attainment of goal BP levels that are main-
tained throughout the entire day and night. Addition-
ally, antihypertensive treatment regimens should be
simple, convenient and well tolerated, and patients
should be supported appropriately to sustain treat-
ment adherence long term. Combination therapy
clearly helps to attain all of these desirable aims.
Meeting BP targets with combination
therapy
More than two-thirds of hypertensive individuals will
require two or more antihypertensive agents selected
from different drug classes to achieve their BP targets
(13,14). For example, in the ALLHAT study, 60% of
those whose BP was controlled to < 140/90 mmHg
received two or more agents, whereas only 30% over-
all were controlled on one drug (14). In the Hyper-
tension Optimal Treatment (HOT) study, only 37%
of patients reached the target diastolic BP
< 90 mmHg with monotherapy (15). Clinical data
show that patients with diabetes mellitus or renal
disease will require greater intensity of antihyperten-
sive treatment to attain their, albeit lower, BP goals.
Accordingly, these hypertensives will require an aver-
age of 2.6 to 4.3 different antihypertensive medica-
tions to achieve a BP goal of lower than 130/
80 mmHg (16). Both the JNC-7 and the 2003 Euro-
pean Society of Hypertension-European Society of
Cardiology guidelines acknowledge that combination
therapy may be necessary and, indeed, ﬁrst-line com-
bination treatment is recommended in JNC-7 for
patients with a BP > 20 mmHg above the systolic
goal or 10 mmHg above the diastolic goal (2,17).
Hypertension guidelines from the International Soci-
ety on Hypertension in Blacks (ISHIB) suggest the
use of combination therapy when BP is > 15 mmHg
above the systolic goal and/or > 10 mmHg above the
diastolic goal (16).
JNC-7 recommends that combination therapy
should usually include a thiazide-type diuretic as
ﬁrst-line therapy for stage 2 hypertension as well as
for patients with compelling indications (2). Accord-
ingly, this article focuses on combination therapy
based on hydrochlorothiazide (HCTZ), speciﬁcally in
combination with ARBs. It should be borne in mind,
however, that combination therapy without thiazides
is also an option as the combination of a calcium
channel blocker with an ACE inhibitor or an ARB
lowers BP very effectively (18,19). Equally, thiazides
may be combined with a range of agents in addition
to the ARBs, including beta blockers, centrally acting
agents and ACE inhibitors (20–22). Each of these
combinations may be appropriate in selected patients
and treatment should be devised on a personalised,
case-by-case basis.
ARBs: clinical potential and
combination with hydrochlorothiazide
Angiotensin receptor blockers have an established
record of BP-lowering efﬁcacy and a placebo-like
side effect proﬁle in hypertensive patients. Recent
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shown that ARBs provide cardiovascular-renal pro-
tection beyond what can be entirely attributed to
BP-lowering alone. In hypertensives with ECG-
LVH, there was a lower incidence of stroke in the
losartan (ARB) than the atenolol (beta-blocker)
treatment arm despite attainment of virtually iden-
tical BP lowering as determined by cuff measure-
ments (23). Losartan-based therapy also proved
superior to a treatment regimen that did not
include either ACE inhibitors or ARBs in slowing
the progressive loss of kidney function in patients
with diabetic nephropathy (24). Irbesartan was
shown to protect against progressive loss of kidney
function and congestive heart failure as well as to
reduce proteinuria more than amlodipine, or a pla-
cebo-based (no ACE, ARB or CCB) treatment regi-
men in hypertensives with diabetic nephropathy
(25,26). Valsartan has been shown to improve out-
comes in heart failure and postmyocardial infarc-
tion (27,28), while candesartan reduces the
incidence of stroke and protects against mortality
and cardiovascular events in patients with heart
failure (29–32). Angiotensin receptor blockers also
lower the incidence of new-onset diabetes (33) and
atrial ﬁbrillation (34).
Notwithstanding these beneﬁts, ARBs like other
classes of antihypertensive do not provide sufﬁcient
BP control for many patients when used in mono-
therapy. Indeed, ARBs, similar to ACE inhibitors,
have near-ﬂat dose–response curves suggesting that
monotherapy dose titration offers limited beneﬁts.
This was shown in a pooled meta analysis of 43
published randomised clinical trials of losartan, val-
sartan, irbesartan and candesartan when adminis-
tered at doses recommended for the treatment of
hypertension (35). ARB monotherapy dose escala-
tion resulted in only a modest incremental diastolic
BP reduction compared with the starting dose of
ARB. However, the near-ﬂat dose response was
resolved by the combination of ARBs with low-dose
diuretics which signiﬁcantly potentiated the BP
reduction.
In addition to their impressive combined
BP-lowering effects, the use of ARBs and HCTZ in
combination counteracts the potential adverse
effects of these agents when given as monotherapy.
Because of the tendency of ARBs to elevate potas-
sium levels, this is less likely to be a problem
when combined with diuretics (36). Likewise, many
of the undesirable metabolic side effects of thiazide
monotherapy, including hypokalaemia, and elevated
serum levels of uric acids, lipids and blood glucose
levels, are minimised by the addition of an ARB
(21,23,37,38).
Tolerability considerations also support the use of
ARBs rather than ACE inhibitors in combination
therapy. For instance, in the recent Blood Pressure
Reduction and Tolerability of Valsartan in Compari-
son With Lisinopril (PREVAIL) trial, patients with
mild-to-moderate hypertension treated with ARB/
HTCZ combination were less likely to experience
adverse events than those treated with ACE-inhibi-
tor/HTCZ combination therapy (5.1% vs. 10.7%,
p ¼ 0.001). Drug-related dry cough also occurred
more frequently in the patients receiving ACE inhibi-
tor (7.2%) than in those receiving ARB (1.0%) (39).
Angioedema, a serious adverse event which can be
life-threatening (40), is experienced much less fre-
quently as a side effect of ARBs, as demonstrated in
the LIFE and VALUE studies (22,23). Hyperkalaemia
has been less common with ARBs than ACE inhibi-
tors in patients with reduced kidney function (41).
These tolerability advantages must be weighed
against the likely lower cost of generic ACE inhibi-
tors, which provide a viable alternative HCTZ com-
bination for patients able to tolerate long-term
treatment.
Fixed-dose combinations of HCTZ and ARBs
provide effective, simple, aggressive and well-toler-
ated BP control and are now rapidly gaining
acceptance with physicians. The usefulness of ARB/
HCTZ combinations in hypertension has now been
demonstrated in clinical trials for most of the
ARBs (42–47). Some of the most detailed recent
data have been obtained with valsartan. In a recent
double-blind, multicenter study of 24 weeks dura-
tion in 1088 patients, ﬁxed-dose combinations of
valsartan 160 mg with HCTZ 15.5 or 25 mg were
found to reduce BP to a similar degree to amlodi-
pine 10 mg (44). However, adverse events were sig-
niﬁcantly less frequent with the ARB/HCTZ
combination and discontinuation rates as a result
of adverse events were 4.2%, 3.5% and 18.2% in
the valsartan/HCTZ 12.5 mg, valsartan/HCTZ
25 mg and amlodipine groups respectively (Fig-
ure 1). These BP-lowering and tolerability beneﬁts
of valsartan have also been reported to be sus-
tained into the long term: in a recent open-label
extension to a 1346-patient study with valsartan,
sustained BP reductions were observed for 1 year,
with mean BP reduced by 24.7/16.6 mmHg in
patient receiving valsartan 320 mg/HCTZ 25 mg
(48). Moreover, the incidence of hypokalaemia was
signiﬁcantly reduced compared with HCTZ mono-
therapy.
In the following section, the data for another rep-
resentative ARB, irbesartan, are reviewed to explore
in greater detail the clinical potential of the ARB/
HCTZ strategy.
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The safety and BP-lowering effect of the combina-
tion of irbesartan plus HCTZ, administered orally
once a day, in patients with hypertension have
been investigated in several clinical trials (Table 1).
The irbesartan/HCTZ combination has been studied
using various doses of each component or as a
ﬁxed dose given in a single tablet. In one study,
patients with hypertension who were non-respon-
sive to 4-week treatment with HCTZ 25 mg con-
tinued with HCTZ and were randomised to receive
either irbesartan or matching placebo for 12 weeks
(49). Irbesartan was given initially at a dose of
75 mg, doubled to 150 mg after 6 weeks for
patients with diastolic BP ‡ 90 mmHg. Signiﬁcant
prompt reductions in BP appeared within 2 weeks
of adding irbesartan. Furthermore at week 12, sig-
niﬁcantly more patients were normalised with irbe-
sartan/HCTZ (67%) compared with placebo/HCTZ
(29%).
The long-term safety and antihypertensive effects
of irbesartan/HCTZ have also been demonstrated
(50). Hypertensive patients completing two rando-
mised, double-blind trials of irbesartan alone, HCTZ
alone, irbesartan/HCTZ or placebo, received irbesar-
tan 75 mg/HCTZ 12.5 mg once daily titrated
to 150 mg/HCTZ 12.5 mg then if necessary
300 mg/HCTZ 25 mg until BP goals were achieved.
If necessary, adjunctive therapies were added. From
months 2 to 12, normalisation rates ranged from
75% to 85% and total responder rates ranged from
81% to 91%, while target BP was achieved in
65–75% of patients. At all time-points, most patients
(> 87%) were receiving irbesartan/HCTZ alone.
There were no reports of serious adverse events
related to study medication.
Another study used a 4 · 4 factorial design or
‘matrix’ design to evaluate irbesartan and HCTZ
across their respective dose ranges in patients with
mild-to-moderate hypertension (45). A total of 683
patients were randomised to receive once-daily dos-
ing with one of the 16 different double-blind, ﬁxed
combinations of irbesartan (0, 37.5, 100 and
300 mg) and HCTZ (0, 6.25, 12.5 and 25 mg).
Mean changes from baseline in trough diastolic BP
ranged from )3.5 mmHg for placebo, )7.1 to )10.2
mmHg for irbesartan monotherapy groups, )5.1 to
)8.3 mmHg for HCTZ monotherapy groups and
)8.1 to )15.0 mmHg for combination therapy
groups. Importantly, irbesartan plus HCTZ produced
additive reductions in BP, with at least one combi-
nation producing greater BP reduction than would
be expected from the combination of both drugs
(p < 0.001). Furthermore, as with other ARB studies,
irbesartan tended to ameliorate the dose-related
Figure 1 Rates of (A) total AEs, (B) total discontinuations and (C) total discontinuations as a result of AEs in the groups
that received valsartan 160 mg plus hydrochlorothiazide 12.5 mg (V + HCTZ12.5), valsartan 160 mg plus HCTZ 25 mg
(V + HCTZ2S) and amlodipine 10 mg (A10) (44)
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alone. No dose-related adverse events were observed,
and the incidence of adverse events and rates of dis-
continuation were comparable between treatment
groups. The authors concluded that the combination
of HCTZ in doses up to 25 mg and irbesartan in
doses up to 300 mg is safe and produces dose-depen-
dent reductions in BP.
Difﬁcult-to-treat patients and severe
hypertension
The combination of an ARB and HCTZ has been
reported to be effective in difﬁcult-to-treat and
severely hypertensive patients for several ARBs,
including losartan, candesartan, telmisartan and
eprosartan (55–58). A high ﬁxed-dose combination
of irbesartan 300 mg/HCTZ 25 mg given once daily
Table 1 Studies of irbesartan/HCTZ in patients with essential hypertension
Study Design/patients/dosage/duration
n (evaluable
for efﬁcacy)
Reduction in SDP/DBP
at end-point
Response rates at
end-point
Randomised blinded
studies
Rosenstock 1998 (49) Single blind, placebo-controlled
Patients unresponsive to HCTZ
Irbesartan 150–300 mg
HCTZ 25 mg
12 weeks
238 (irbesartan 118,
placebo 120)
11.1/7.2 mmHg (vs. placebo;
p < 0.01)
67% (vs. 29% placebo;
p < 0.01)
Kochar 1999 (45) Double-blind, placebo-controlled,
matrix design
Mild-to-moderate hypertension
Irbesartan 0, 37.5, 100 or 300 mg
HCTZ 0, 6.25,12.5 or 25 mg
8 weeks
630 (300/25 mg,
n ¼ 41)
23.1/14.4 mmHg (300/25 mg) 44–80% with
increasing dose
Bobrie 2005
(COSIMA study) (52)
Double-blind, comparative
Untreated or uncontrolled hypertensives
Irbesartan/HCTZ 150/12.5 mg
Valsartan/HCTZ 80/12.5 mg
8 weeks
449 (irbesartan 222,
valsartan 227)
Irbesartan 14/10.3 mmHg
Valsartan 11.9/8.4 mmHg
(Evening measurements,
home BP monitoring)
50.2% (irbesartan)
33.2% (valsartan)
(p < 0.01; normalised;
home BP monitoring)
Neutel 2006 (61) Double-blind, comparative
Severe hypertension
Forced titration
Irbesartan/HCTZ 300/25 mg
Irbesartan monotherapy 300 mg
7 weeks
737 (irbesartan/HCTZ 468,
irbesartan 269)
9.7/4.7 mmHg (combination
therapy vs. monotherapy;
p < 0.0001)
47.2% (combination
therapy)
33.2% (monotherapy)
p ¼ 0.0005; seated
DBP < 90 mmHg)
Selected non-blinded studies
Raskin 1999 (50) Open-label extension of two randomised,
double-blind trials
Mild-to-moderate hypertension
Irbesartan/HCTZ 75/12.5–300/25 mg
1 year
1098 20.6/15.6 mmHg 83% normalised
90% responded
70% achieved speciﬁed
BP goals
Neutel 2005
(INCLUSIVE study) (61)
Open-label study
Hypertensives with uncontrolled systolic
blood pressure
Irbesartan/HCTZ 150/12.5 mg–300/25 mg
16 weeks (after 4–5 weeks placebo & 2
weeks HCTZ run-in)
844 21.5/10.4 mmHg 69% achieved speciﬁed
BP goals
Coca 2003 (59) Open-label study
Hypertension uncontrolled by
monotherapy/low-dose
combination therapy
Irbesartan/HCTZ 300/25 mg
12 weeks
57 25.2/14.7 mmHg (ambulatory
BP measurements,
peak levels)
94.7% SBP responders
87.7% DBP responders
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previously uncontrolled hypertension (59). As well as
signiﬁcantly reducing both clinic and ambulatory BP,
12 weeks of treatment preserved the circadian proﬁle
as shown by trough-to-peak ratios and smoothness
index values for both systolic BP and diastolic BP
(Figure 2). No metabolic changes were observed at
these doses, and no patient discontinued the study
because of treatment-related side effects.
The IrbesartaN/HCTZ bLood pressUre reductionS
in dIVErse populations (INCLUSIVE) trial was a
multicenter, prospective, open-label, single arm study
to evaluate the BP-lowering efﬁcacy and safety of a
ﬁxed-dose combination of irbesartan and HCTZ, at
low dose (150 mg/12.5 mg) and at high dose
(300 mg/25 mg) sequentially for 8 weeks each. Each
combination of irbesartan and HCTZ was adminis-
tered as a single tablet. Treatment was given to over
800 difﬁcult-to-treat hypertensive patients including
the elderly people, African-Americans, Hispanics,
patients with type 2 diabetes and patients with the
metabolic syndrome (60). Overall, 77% of patients
achieved systolic BP control, and 83% achieved dia-
stolic BP control after 8–16 weeks of treatment. The
mean change in diastolic BP from baseline to the
end of treatment was )10.4 ± 8.7 mmHg
(p < 0.001) and the mean change in systolic BP was
)21.5 ± 14.3 mmHg (p < 0.001). Further subanaly-
ses showed that 96% of elderly patients achieved dia-
stolic BP control and 73% achieved systolic BP. Over
70% of the elderly people, African-Americans, His-
panic/Latinos, those with metabolic syndrome,
women and men achieved both systolic and diastolic
BP control (60). Combination therapy was well toler-
ated and the results consistent across diverse patient
populations.
Irbesartan has also been investigated in severely
hypertensive patients. In a randomised, double-blind
study of 737 patients with severe hypertension, 468
patients were given ﬁxed-dose irbesartan/HCTZ 150/
12.5 mg for 1 week then were force-titrated to a 300/
25 mg dose for a further 6 weeks (61). The remain-
ing 269 patients received irbesartan 150 mg mono-
therapy force-titrated to 300 mg monotherapy. At
week 5, signiﬁcantly more patients on combination
therapy achieved the primary end-point of a seated
DBP < 90 mmHg (47.2% vs. 33.2% respectively;
p ¼ 0.0005). More patients also reached the JNC-7
Figure 2 Comparison of the antihypertensive effects of irbesartan/HCTZ (150/12.5 mg) and valsartan/HCTZ (80/12.5 mg)
in hypertensive patients: the COSIMA study (52). Reprinted with permission from the American Journal of Hypertension,
Ltd
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respectively; p < 0.0001). Importantly, the rate at
which BP control was achieved was also signiﬁcantly
more rapid in the irbesartan group (Figure 3). These
effects were achieved without additional side effects.
Comparative studies
Angiotensin receptor blockers used in monotherapy
have been widely reported to vary in their BP-lower-
ing efﬁcacy. For instance, irbesartan at a starting
dose of 150 mg has been reported to reduce BP more
effectively than valsartan at its original starting dose
of 80 mg (51). However, reported differences
between ARBs generally reﬂect disparities between
the doses selected for study. While the potency of
individual molecules within the ARB class may
indeed vary, with appropriate dosing their antihyper-
tensive efﬁcacy is broadly similar. In the aftermath of
the VALUE trial, higher doses of valsartan are
increasingly being used, and a starting dose of
160 mg would now be considered more appropriate
than the 80 mg used in most comparative trials pub-
lished to date.
Similar differences in BP-lowering efﬁcacy have
been reported in the ﬁxed-dose combination setting,
although the same difﬁculties with dose selection
exist. The recent COmparative Study of efﬁcacy of
Irbesartan/HCTZ with valsartan/HCTZ using home
blood pressure Monitoring in the treAtment of
mild-to-moderate hypertension (COSIMA) study
demonstrated greater antihypertensive efﬁcacy of the
ﬁxed-dose combination of irbesartan 150 mg/HCTZ
12.5 mg vs. a ﬁxed-dose combination of valsartan
80 mg/HCTZ 12.5 mg in an 8-week study of 414
hypertensive patients uncontrolled on HCTZ (52),
although with a higher dose of valsartan greater par-
ity might have been expected.
Differences in antihypertensive efﬁcacy have also
been reported between various other ARB/HCTZ
combinations. For instance, in a recent 8-week study
in 1066 patients, telmisartan/HCTZ 80/25 mg was
reported to reduce both systolic and diastolic BP to
a greater degree than valsartan/HCTZ 160/25 mg
(53). Once again, however, it should be noted that
telmisartan was used at its current maximum dose,
whereas valsartan’s maximum dose is now 320 mg.
In a smaller study in 130 patients with hypertension
uncontrolled by monotherapy, the addition of HCTZ
12.5 mg to valsartan 160 mg was recently reported to
lead to greater additional reductions in BP than
when added to olmesartan 20 mg (54); however,
Figure 3 Percentage of patients achieving SeDBP < 90 mmHg during 7 weeks’ double-blind treatment of irbesartan/HCTZ
combination therapy vs. irbesartan monotherapy (61)
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doses, these results are difﬁcult to evaluate.
In conclusion, it remains difﬁcult to rank ARB/
HCTZ combinations in terms of basic BP-reducing
efﬁcacy, as relatively few head-to-head trials have
been carried out and the majority have not com-
pared agents at like-for-like doses and with respect
to universally agreed end-points. The goal of treat-
ment should therefore be to treat patients to target
irrespective of which particular ARB/HCTZ combi-
nation is used, with prompt dose escalation and the
addition of a third agent whenever necessary to
achieve this goal.
Irbesartan reduces albuminuria
independent of blood pressure
lowering
This study highlights an intriguing aspect of therapy
with angiotensin receptor blockade. That is, the
dose–response curves for BP-lowering and
target-organ protection are not identical. In this dou-
ble-masked, randomised, crossover study in 52
hypertensive persons with type 2 diabetes and micro-
albuminuria, all treated with bendroﬂumethiazide
5 mg/day, irbesartan was also administered in doses
of 300, 600, and 900 mg/day (62). Urinary albumin
excretion was lowered an additional 15% more with
900 mg/day of irbesartan compared with lower doses;
ambulatory SBP was lowered by 8, 9, and 9 mmHg,
respectively, with higher irbesartan doses. These data
show incremental target-organ protection with doses
of irbesartan much higher than the FDA-approved
dose for hypertension (300 mg/day) that appears dis-
tinct from the magnitude of BP lowering.
Conclusions
There is a need for effective, safe and simple thera-
pies to treat hypertension to recommended BP tar-
gets rapidly and rigorously, but with good
tolerability and sustained patient adherence. The use
of combination therapy as ﬁrst-line treatment will
help more patients promptly achieve BP goals, and
ﬁxed-dose combinations provide a means for simple
but ﬂexible dosing. Combination therapy using ARBs
with HCTZ provides greater potency and fewer side
effects than higher-dose monotherapy with either
agent, and potentially offers beneﬁts beyond those of
BP lowering alone, particularly in high-risk hyperten-
sives. The results from the irbesartan/HCTZ studies
illustrate the potential of ARB/HCTZ therapy as a
starting treatment in patients with moderate and
severe hypertension; in patients with stage 2 disease
such treatment enables management goals speciﬁed
by current guidelines to be more rapidly and effec-
tively achieved.
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